OMER – Omeros Corporation
OMER — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
21.62
Margin Of Safety %
Put/Call OI Ratio
0.48
EPS Next Q Diff
-0.88
EPS Last/This Y
-0.15
EPS This/Next Y
0.58
Price
13.27
Target Price
33
Analyst Recom
2.33
Performance Q
-9.49
Upside
127.2%
Beta
2.54
Ticker: OMER
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | OMER | 10 | 0.71 | 0.16 | 98788 |
| 2026-07-14 | OMER | 10.5 | 0.71 | 4.65 | 98994 |
| 2026-07-15 | OMER | 10.35 | 0.76 | 0.33 | 104722 |
| 2026-07-16 | OMER | 9.22 | 0.76 | 0.15 | 107356 |
| 2026-07-17 | OMER | 9.68 | 0.72 | 0.23 | 106845 |
| 2026-07-20 | OMER | 9.62 | 0.55 | 0.18 | 75045 |
| 2026-07-21 | OMER | 9.52 | 0.54 | 0.09 | 76897 |
| 2026-07-22 | OMER | 9.84 | 0.53 | 0.01 | 78084 |
| 2026-07-23 | OMER | 10.28 | 0.52 | 0.43 | 79262 |
| 2026-07-24 | OMER | 9.77 | 0.53 | 0.07 | 82375 |
| 2026-07-27 | OMER | 11.35 | 0.53 | 0.34 | 82604 |
| 2026-07-28 | OMER | 11.29 | 0.50 | 0.15 | 93064 |
| 2026-07-29 | OMER | 11.69 | 0.50 | 0.13 | 94053 |
| 2026-07-30 | OMER | 11.92 | 0.49 | 0.14 | 95279 |
| 2026-07-31 | OMER | 11.86 | 0.48 | 0.86 | 96854 |
| 2026-08-03 | OMER | 12.56 | 0.48 | 0.09 | 96818 |
| 2026-08-04 | OMER | 12.96 | 0.47 | 0.33 | 97627 |
| 2026-08-05 | OMER | 12.64 | 0.47 | 0.04 | 98111 |
| 2026-08-07 | OMER | 13.28 | 0.48 | 0.03 | 96659 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | OMER | 10.01 | 149.9 | - | 0.38 |
| 2026-07-14 | OMER | 10.49 | 149.9 | - | 0.38 |
| 2026-07-15 | OMER | 10.35 | 149.9 | - | 0.38 |
| 2026-07-16 | OMER | 9.22 | 149.9 | - | 0.38 |
| 2026-07-17 | OMER | 9.68 | 149.9 | - | 0.38 |
| 2026-07-20 | OMER | 9.62 | 149.9 | - | 0.38 |
| 2026-07-21 | OMER | 9.53 | 149.9 | - | 0.38 |
| 2026-07-22 | OMER | 9.84 | 149.9 | - | 0.38 |
| 2026-07-23 | OMER | 10.30 | 149.9 | - | 0.38 |
| 2026-07-24 | OMER | 9.77 | 149.9 | - | 0.38 |
| 2026-07-27 | OMER | 11.35 | 149.9 | - | 0.38 |
| 2026-07-28 | OMER | 11.29 | 149.9 | - | 0.38 |
| 2026-07-29 | OMER | 11.68 | 149.9 | - | 0.38 |
| 2026-07-30 | OMER | 11.91 | 149.9 | - | 0.38 |
| 2026-07-31 | OMER | 11.86 | 37.9 | - | -0.20 |
| 2026-08-03 | OMER | 12.55 | 37.9 | - | -0.20 |
| 2026-08-04 | OMER | 12.55 | 37.9 | - | -0.20 |
| 2026-08-05 | OMER | 12.65 | 37.9 | - | -0.20 |
| 2026-08-06 | OMER | 13.15 | 37.9 | - | -0.20 |
| 2026-08-07 | OMER | 13.27 | 37.9 | - | -0.20 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | OMER | -2.55 | -4.08 | 21.69 |
| 2026-07-14 | OMER | -2.55 | -4.08 | 21.69 |
| 2026-07-15 | OMER | -0.29 | -4.08 | 21.69 |
| 2026-07-16 | OMER | -0.29 | -4.08 | 21.69 |
| 2026-07-17 | OMER | -0.29 | -4.08 | 21.69 |
| 2026-07-20 | OMER | -0.29 | -3.96 | 21.69 |
| 2026-07-21 | OMER | -0.29 | -3.96 | 21.69 |
| 2026-07-22 | OMER | -0.29 | -3.96 | 21.69 |
| 2026-07-23 | OMER | -0.29 | -3.96 | 21.69 |
| 2026-07-24 | OMER | -0.29 | -3.96 | 21.69 |
| 2026-07-27 | OMER | -0.29 | -3.91 | 21.62 |
| 2026-07-28 | OMER | -0.29 | -3.91 | 21.62 |
| 2026-07-29 | OMER | -0.29 | -3.91 | 21.62 |
| 2026-07-30 | OMER | -0.29 | -3.91 | 21.62 |
| 2026-07-31 | OMER | -0.29 | -3.91 | 21.62 |
| 2026-08-03 | OMER | -0.29 | -3.45 | 21.62 |
| 2026-08-04 | OMER | -0.29 | -3.45 | 21.62 |
| 2026-08-05 | OMER | -0.29 | -3.45 | 21.62 |
| 2026-08-06 | OMER | -0.29 | -3.45 | 21.62 |
| 2026-08-07 | OMER | -0.29 | -3.45 | 21.62 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.57
Avg. EPS Est. Current Quarter
-0.33
Avg. EPS Est. Next Quarter
-0.31
Insider Transactions
-0.29
Institutional Transactions
-3.45
Beta
2.54
Average Sales Estimate Current Quarter
12
Average Sales Estimate Next Quarter
17
Fair Value
Quality Score
56
Growth Score
25
Sentiment Score
73
Actual DrawDown %
24.8
Max Drawdown 5-Year %
-93.4
Target Price
33
P/E
15.48
Forward P/E
175.8
PEG
P/S
96.96
P/B
P/Free Cash Flow
EPS
0.86
Average EPS Est. Cur. Y
-0.2
EPS Next Y. (Est.)
0.38
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
871.02
Relative Volume
0.66
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
-0.6
EPS 1 30Days Diff
-0.58
EBIT Estimation
◆
OMER
Healthcare
$13.25
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
69.3
Range 1M
91.6%
Sup Dist
5.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
18.7%
EPS NY
285.3%
52W%
66.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+42.9% upside
Upside
+42.9%
Quality
56
OMER — P/E HistoricalBiotechnology
Omeros CorporationSector: Healthcare
Industry: Biotechnology
Employees: 175
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER
Latest News
—
Caricamento notizie per OMER…
stock quote shares OMER – Omeros Corporation Stock Price stock today
news today OMER – Omeros Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch OMER – Omeros Corporation yahoo finance google finance
stock history OMER – Omeros Corporation invest stock market
stock prices OMER premarket after hours
ticker OMER fair value insiders trading